Clinical Trials Logo

Clinical Trial Summary

This is a multi-site, open-label, Phase II, randomized, trial to compare the efficacy of RO7198457 versus watchful waiting in patients with circulating tumor DNA (ctDNA) positive, surgically resected Stage II/III rectal cancer, or Stage II (high risk)/Stage III colon cancer.


Clinical Trial Description

Patients will receive up to 15 doses of RO7198457 over the course of trial treatment. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04486378
Study type Interventional
Source BioNTech SE
Contact BioNTech clinical trials patient information
Phone +49 6131 9084
Email patients@biontech.de
Status Recruiting
Phase Phase 2
Start date March 8, 2021
Completion date July 2027

See also
  Status Clinical Trial Phase
Completed NCT01570452 - Matrilysin Expression in Different Stages of Colorectal Tumors N/A
Active, not recruiting NCT04304209 - Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer Phase 2
Active, not recruiting NCT04398446 - Effect of Hemp-CBD on Patients With CIPN Phase 2
Recruiting NCT04264676 - Study of Oral Metronidazole on Postoperative Chemotherapy in Colorectal Cancer Phase 2
Recruiting NCT06314958 - Stage II/III Colorectal Cancer Recurrence
Recruiting NCT06342440 - Early Detection of Advanced Adenomas and Colorectal Cancer
Recruiting NCT04714814 - Mechanisms of Fate Evolution of Colorectal Adenocarcinoma Metastasis
Recruiting NCT05898789 - Virtual Rehabilitation for Cancer Survivors N/A
Completed NCT01356264 - Multimodal Prehabilitation for Colorectal Surgery Phase 2
Recruiting NCT04813627 - Epidemiological Study to Monitor Study Participants With Resected Stage II (High Risk) or Stage III Colorectal Cancer for Circulating Tumor DNA Before, During and After Their Treatment With Adjuvant Chemotherapy
Recruiting NCT03448549 - SOX Versus XELOX as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients Phase 3
Recruiting NCT03904537 - A Study of Combination of Anti-PD1 Antibody-activated TILs and Chemotherapy in Colorectal Cancer Phase 1/Phase 2
Not yet recruiting NCT05131243 - the Role of ctDNA in Predicting the Recurrence Risk of Colorectal Cancer N/A
Recruiting NCT06076811 - DANISH.MRD: Danish Assessment of Minimal Residual Disease by Liquid Biopsies
Recruiting NCT06111105 - Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Colorectal Cancer
Recruiting NCT06342401 - Early Onset Colorectal Cancer Detection
Completed NCT06271980 - Early-Onset Colorectal Cancer Recurrence